Citations

Mayo Clinic

Showing 10 of 108551 citations.

Biventricular catheterization combined with pressure‐volume loop monitoring provides insight into the dynamic effects of left ventricular assist devices ramp on right ventricular function
Garmany, Armin , Inglis, Sara S. , Rosenbaum, Andrew , Rosenbaum, Andrew N , Inglis, Sara S , Behfar, Atta

Catheterization and Cardiovascular Interventions | March 10, 2024 | Volume: 103 | Issue: 5 | Pages: 799-802

10.1002/ccd.30993 | PMID 38461378 Get It

AbstractRamp studies are utilized for speed optimization of continuous flow left ventricular assist devices (CF‐LVADs). We here report the utility of combined left and right heart catheterization during a ramp study to ensure a comprehensive understanding of the hemodynamic implications on both ventricles. Pressure‐volume loop (PV loop) monitoring uncovered compromised systolic and mildly compromised right ventricular function with increasing LVAD speeds, despite improvement in left ventricular unloading. These findings informed patient management and highlight the potential utility of PV loop monitoring as an adjunct to left and right heart catheterization during ramp studies of next‐generation LVADs.
Inter-atrial Septal Balloon Dilation to Facilitate Intracardiac Echocardiography Guided Left Atrial Appendage Occlusion
Goyal, Sandeep , Bhimani, Ashish A. , Kella, Danesh , Tyagi, Anahita , Polsani, Venkateshwar , Deering, Thomas F. , Kella, Danesh K , Goyal, Sandeep K

No container title available | March 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.171004751.17002918/v1 Get It

Background: Percutaneous left atrial appendage occlusion (LAAO) is traditionally performed under general anesthesia with trans-esophageal echocardiography guidance. Intracardiac echo (ICE) guided LAAO closure is increasing in clinical use. The ICE catheter is crossed into LA via interatrial septum (IAS) after the septum is dilated with LAAO delivery sheath. This step can be time-consuming and requires significant ICE catheter manipulation increasing the risk of cardiac perforation. Pre-emptive septal balloon dilation can potentially help with the advancement of ICE in LA. Objective: Evaluate the effect of pre-dilation of IAS with an 8 mm balloon on ease of crossing the ICE catheter, fluoroscopy time for crossing, and overall procedure time. Methods: The Piedmont LAAO registry was used to identify consecutive patients undergoing LAAO. The initial 25 patients where balloon dilation of IAS was performed served as the experimental cohort, and the 25 consecutive patients prior to that in whom balloon dilation was not performed, served as controls. For the experimental group, after a trans-septal puncture, the sheath was retracted to the right atrium with guide wire still in the LA. An 8x40 mm Evercoss™ over the wire balloon was inflated across the IAS. The ICE catheter was then crossed into the LA using the fluoroscopic landmark of the guide wire and the ICE imaging. The sheath was then advanced along the ICE catheter via the transseptal puncture (TSP) and the procedure continued. Follow up CT imaging was obtained in 4-8 weeks. Results: Each group included 25 patients. There were no significant differences in baseline characteristics. All procedures were performed successfully with the use of conscious sedation and ICE guidance. There was a significant reduction in overall procedure time, fluoroscopy time, and time for trans-septal puncture to ICE in LA. There was no difference in the size of the acute residual interatrial shunt as measured via ICE or size and presence of iatrogenic ASD at follow up. Conclusion: Balloon dilation of TSP is safe and associated with increased efficiencies in ICE guided LAAO procedures.
High yield clinical applications for photon counting CT in neurovascular imaging
Madhavan, Ajay A. , Nagelschneider, Alex A. , Benson, John C. , Diehn, Felix E. , Lehman, Vance T. , Madhavan, Ajay A , Bathla, Girish

British Journal of Radiology | March 10, 2024 | Volume: 97 | Issue: 1157 | Pages: 894-901

10.1093/bjr/tqae058 | PMID 38460543 Get It

Abstract Photon-counting CT (PCCT) uses a novel X-ray detection mechanism that confers many advantages over that used in traditional energy integrating CT. As PCCT becomes more available, it is important to thoroughly understand its benefits and highest yield areas for improvements in diagnosis of various diseases. Based on our early experience, we have identified several areas of neurovascular imaging in which PCCT shows promise. Here, we describe the benefits in diagnosing arterial and venous diseases in the head, neck, and spine. Specifically, we focus on applications in head and neck CT angiography (CTA), spinal CT angiography, and CT myelography for detection of CSF-venous fistulas. Each of these applications highlights the technological advantages of PCCT in neurovascular imaging. Further understanding of these applications will not only benefit institutions incorporating PCCT into their practices but will also help guide future directions for implementation of PCCT for diagnosing other pathologies in neuroimaging.
Algorithmic Identification of Treatment‐Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease
Silverman, Anna L. , Sushil, Madhumita , Bhasuran, Balu , Ludwig, Dana , Buchanan, J.R. , Racz, Rebecca , Parakala, Mahalakshmi, El‐Kamary, Samer S., Ahima, Ohenewaa, Belov, Artur , Choi, Lauren , Billings, Monisha , Li, Yan , Habal, Nadia, Tiwari, Jawahar L., Butte, Atul J. , Buchanan, James , Liu, Qi , Butte, Atul J , Rudrapatna, Vivek A , Silverman, Anna Lerman

Clinical Pharmacology & Therapeutics | March 9, 2024 | Volume: 115 | Issue: 6 | Pages: 1391-1399

10.1002/cpt.3226 | PMID 38459719 Get It

Outpatient clinical notes are a rich source of information regarding drug safety. However, data in these notes are currently underutilized for pharmacovigilance due to methodological limitations in text mining. Large language models (LLMs) like Bidirectional Encoder Representations from Transformers (BERT) have shown progress in a range of natural language processing tasks but have not yet been evaluated on adverse event (AE) detection. We adapted a new clinical LLM, University of California – San Francisco (UCSF)‐BERT, to identify serious AEs (SAEs) occurring after treatment with a non‐steroid immunosuppressant for inflammatory bowel disease (IBD). We compared this model to other language models that have previously been applied to AE detection. We annotated 928 outpatient IBD notes corresponding to 928 individual patients with IBD for all SAE‐associated hospitalizations occurring after treatment with a non‐steroid immunosuppressant. These notes contained 703 SAEs in total, the most common of which was failure of intended efficacy. Out of eight candidate models, UCSF‐BERT achieved the highest numerical performance on identifying drug‐SAE pairs from this corpus (accuracy 88–92%, macro F1 61–68%), with 5–10% greater accuracy than previously published models. UCSF‐BERT was significantly superior at identifying hospitalization events emergent to medication use ( P < 0.01). LLMs like UCSF‐BERT achieve numerically superior accuracy on the challenging task of SAE detection from clinical notes compared with prior methods. Future work is needed to adapt this methodology to improve model performance and evaluation using multicenter data and newer architectures like Generative pre‐trained transformer (GPT). Our findings support the potential value of using large language models to enhance pharmacovigilance.
Incidence of and risk factors for chronic subdural hematoma after endoscopic endonasal surgery: quantitative analysis of pneumocephalus
Umekawa, Motoyuki , Hasegawa, Hirotaka , Shinya, Yuki , Shin, Masahiro , Shinya, Yuki , Saito, Nobuhito

Journal of Neurosurgery | March 9, 2024 | Volume: 141 | Issue: 2 | Pages: 484-490

10.3171/2024.1.jns231953 | PMID 38457806 Get It

OBJECTIVE Chronic subdural hematoma (CSDH) is known to occur after endoscopic endonasal surgery (EES); however, the detailed clinical picture remains unclear. In this study, the authors aimed to examine the incidence of and risk factors for post-EES CSDH, with a focus on the quantitative evaluation of postoperative pneumocephalus. METHODS The authors retrospectively collected data on consecutive patients who, between November 2016 and December 2022, had undergone EES during which intraoperative cerebrospinal fluid (CSF) leakage occurred. Using CT images obtained immediately after surgery (CT0), the authors measured the extent of pneumocephalus in detail. The locations of pneumocephalus were divided into two groups: remote and local. Remote pneumocephalus was further subdivided into convexity and ventricular. The incidence of post-EES CSDH was calculated, and its risk factors were analyzed. RESULTS Among the 159 EES patients included in the study, Esposito grade 1, 2, and 3 intraoperative CSF leakage was confirmed in 22 (14%), 27 (17%), and 110 (69%) patients, respectively. CSDH occurred in 6 patients (3.8%). One patient (0.6%) required unilateral burr hole surgery, whereas the hematomas spontaneously disappeared in the others. All CSDHs occurred in patients with Esposito grade 3 CSF leakage and convexity pneumocephalus on CT0. In the multivariate analysis of 149 sides with convexity pneumocephalus on CT0, the product of the diameter and the thickness of convexity pneumocephalus on CT0 was significantly associated with subsequent CSDH (OR 1.21, 95% CI 1.06–1.38, p = 0.004). Using a cutoff value of 10 cm2, CSDH development could be predicted with a sensitivity of 0.82 and specificity of 0.74. CONCLUSIONS The incidence of post-EES CSDH is acceptably low, and surgery is rarely required. Patients with extensive convexity pneumocephalus on immediate postoperative CT are prone to develop CSDH and thus should be carefully monitored.
Differentiating anorexia nervosa and atypical anorexia nervosa with absolute weight cut‐offs results in a skewed distribution for premorbid weight among youth
Matthews, Abigail , Lin, Jessica , Jhe, Grace , Peters, Triinu , Sim, Leslie , Hebebrand, Johannes , Matthews, Abigail , Peters, Triinu

International Journal of Eating Disorders | March 8, 2024 | Volume: 57 | Issue: 4 | Pages: 983-992

10.1002/eat.24188 | PMID 38459568 Get It

Abstract Objective Anorexia nervosa (AN) and atypical AN are conceptualized as distinct illnesses, despite similar characteristics and sequelae. Whereas DSM‐5 differentiates youth with AN and atypical AN by the presence of clinical ‘underweight’ (i.e., 5th BMI percentile for age‐and‐sex (BMI%)), we hypothesized that using this weight cut‐off to discern diagnoses creates a skewed distribution for premorbid weight. Method Participants included hospitalized youth with AN ( n = 165, 43.1%) and atypical AN ( n = 218, 56.9%). Frequency analyses and chi‐square tests assessed the distribution of premorbid BMI z ‐scores (BMIz) for diagnosis. Non‐parametric Spearman correlations and Stepwise Linear regressions examined relationships between premorbid BMIz, admission BMIz, and weight loss in kg. Results Premorbid BMIz distributions differed significantly for diagnosis ( p < .001), with an underrepresentation of ‘overweight/obesity’ (i.e., BMI% ≥ 85th) in AN. Despite commensurate weight loss in AN and atypical AN, patients with premorbid ‘overweight/obesity’ were 8.31 times more likely to have atypical AN than patients with premorbid BMI% < 85th. Premorbid BMIz explained 57% and 39% of the variance in admission BMIz and weight loss, respectively. Discussion Findings support a homogenous model of AN and atypical AN, with weight loss predicted by premorbid BMI in both illnesses. Accordingly, premorbid BMI and weight loss (versus presenting BMI) may better denote the presence of an AN‐like phenotype across the weight spectrum. Findings also suggest that differentiating diagnoses with BMI% < 5th requires that youth with higher BMIs lose disproportionately more weight for an AN diagnosis. This is problematic given unique treatment barriers experienced in atypical AN. Public significance Anorexia nervosa (AN) and atypical AN are considered distinct conditions in youth, with differential diagnosis hinging upon a presenting weight status of ‘underweight’ (i.e., BMI percentile for age‐and‐sex (BMI%) < 5th). In our study, youth with premorbid ‘overweight/obesity’ (BMI% ≥ 85th) disproportionately remained above this threshold, despite similar weight loss. Coupled with prior evidence for commensurate characteristics and sequelae in both diagnoses, we propose that DSM‐5 differentiation of AN and atypical AN inadvertently reinforces weight stigma and may contribute to treatment disparities in atypical AN.
The critical role of muscularis macrophages in modulating the enteric nervous system function and gastrointestinal motility
Choi, Egan L. , Taheri, Negar , Zhang, Yuebo , Matsumoto, Kenjiro, Hayashi, Yujiro

Journal of Smooth Muscle Research | March 8, 2024 | Volume: 60 | Pages: 1-9

10.1540/jsmr.60.1 | PMID 38462479 Get It

Redefining Patient Evaluation in Anti-IgLON5 Disease
Dubey, Divyanshu , Thakolwiboon, Smathorn , Dubey, Divyanshu

Neurology | March 8, 2024 | Volume: 102 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000209213 | PMID 38457770 Get It

A Case of Early Morphea Mimicking Hypopigmented Mycosis Fungoides in a Pediatric Patient
Colbert, Michelle D. , Youssef, Molly J. , Lehman, Julia S. , Johnson, Emma F. , Lehman, Julia S

The American Journal of Dermatopathology | March 8, 2024 | Volume: 46 | Issue: 4 | Pages: 235-237

10.1097/dad.0000000000002646 | PMID 38457743 Get It

HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405
Battaglin, Francesca , Ou, Fang‐Shu , Qu, Xueping , Höchster, Howard S. , Niedzwiecki, Donna , Goldberg, Richard M. , Ashouri, Karam , Blanke, Charles D. , Kabbarah, Omar , Lenz, Heinz‐Josef , Innocenti, Federico , Ashouri, Karam , Zemla, Tyler J, Venook, Alan P , Lenz, Heinz-Josef , Innocenti, Federico , Ou, Fang-Shu , Niedzwiecki, Donna , Mayer, Robert J. , Zemla, Tyler , Venook, Alan P.

Journal of Clinical Oncology | March 8, 2024 | Volume: 42 | Issue: 16 | Pages: 1890-1902

10.1200/jco.23.01507 | PMID 38457761 Get It

PURPOSE The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of HER2 amplification and gene expression using next-generation sequencing (NGS) and NanoString data. PATIENTS AND METHODS Primary tumor DNA from 559 patients was profiled for HER2 amplification by NGS (FoundationOne CDx). Tumor tissue from 925 patients was tested for NanoString gene expression using an 800-gene panel. OS and progression-free survival (PFS) were the time-to-event end points. RESULTS High HER2 expression (dichotomized at median) was associated with longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment. An OS benefit for cetuximab versus bevacizumab was observed in the high HER2 expression group ( P = .02), whereas a worse PFS for cetuximab was seen in the low-expression group ( P = .019). When modeled as a continuous variable, increased HER2 expression was associated with longer OS (hazard ratio [HR], 0.83 [95% CI, 0.75 to 0.93]; adjusted P = .0007) and PFS (HR, 0.82 [95% CI, 0.74 to 0.91]; adjusted P = .0002), reaching a plateau effect after the median. In patients with HER2 expression lower than median, treatment with cetuximab was associated with worse PFS (HR, 1.38 [95% CI, 1.12 to 1.71]; adjusted P = .0027) and OS (HR, 1.28 [95% CI, 1.02 to 1.59]; adjusted P = .03) compared with that with bevacizumab. A significant interaction between HER2 expression and the treatment arm was observed for OS ( P intx = .017), PFS ( P intx = .048), and objective response rate ( P intx = .001). CONCLUSION HER2 gene expression was prognostic and predictive in CALGB/SWOG 80405. HER2 tumor expression may inform treatment selection for patients with low HER2 favoring bevacizumab- versus cetuximab-based therapies.